(Q40662825)

English

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri

scientific article published on 20 May 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority tri (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Ursula Vehling-Kaiser

12

object named as

Ursula Vehling-Kaiser

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Clemens-Martin Wendtner

21

object named as

Clemens-Martin Wendtner

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Barbara Eichhorst

1

object named as

Barbara Eichhorst

0 references

Stephan Stilgenbauer

24

object named as

Stephan Stilgenbauer

0 references

object named as

Marek Trneny

17

0 references

26

object named as

Michael Hallek

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

3

object named as

Jasmin Bahlo

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

author name string

Anna-Maria Fink

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Raymonde Busch

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Gabor Kovacs

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Christian Maurer

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Elisabeth Lange

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Hubert Köppler

8

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Michael Kiehl

9

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Martin Sökler

10

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Rudolf Schlag

11

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Georg Köchling

13

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Christoph Plöger

14

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Michael Gregor

15

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Torben Plesner

16

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Kirsten Fischer

18

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Harmut Döhner

19

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Michael Kneba

20

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Wolfram Klapper

22

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Karl-Anton Kreuzer

23

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sebastian Böttcher

25

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

international group of investigators

27

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

German CLL Study Group (GCLLSG)

28

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

publication date

20 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

928-942

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Chronic lymphocytic leukemia in young (≤ 55 years) patients: a comprehensive analysis of prognostic factors and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbidity and functional status are independent in older cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Suboptimal dosing of rituximab in male and female patients with DLBCL.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930051-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30051-1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40662825&oldid=1561860085"